Ed oversees Lilly Ventures and he brings three decades of pharmaceutical and venture capital experience to the team. Since co-founding Lilly Ventures in late 2001, he has led the investments in, and served on the boards of, several biotech companies including the Fund’s successful exits of Receptos, Coherus, Conforma and Serenex, as well as current investments in Innocrin Pharmaceuticals and Viamet Pharmaceuticals. Ed also serves on several social services non-profit boards.
Prior to his role in Lilly Ventures, Ed had a diverse set of experiences throughout the domestic and international pharmaceutical businesses including operational finance, planning, M&A, business development, and global marketing roles.
Ed received a Bachelor of Arts from Creighton University and a Master of Business Administration from the University of Michigan’s Ross School of Business, where he was a Consortium Fellow.